# Diclofenac for Prevention of Post-ERC Pancreatitis

> **NCT03595150** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Karolinska Institutet** · enrollment: 1000 (estimated)

## Conditions studied

- Common Bile Duct Diseases

## Interventions

- **DRUG:** Diclofenac

## Key facts

- **NCT ID:** NCT03595150
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03595150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03595150, "Diclofenac for Prevention of Post-ERC Pancreatitis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03595150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*